SCHEMBL21183478

SCHEMBL21183478

CC(=O)OC1CCC2(C)C3=C(CCC2C1(C)C)C1(C)CCC([C@H](C)CC/C=C(/C)C(=O)O)C1(C)CC3

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.85
USP2 O75604 2/20 0.85
ALDH1A1 P00352 2/20 0.85
CYP3A4 P08684 2/20 0.85
ALOX15 P16050 2/20 0.85
PTGES O14684 4/20 0.75
MEN1 O00255 1/20 0.72
PLA2G1B P04054 1/20 0.72
DNMT1 P26358 1/20 0.72
BLM P54132 1/20 0.72
KMT2A Q03164 1/20 0.72
ATG4B Q9Y4P1 1/20 0.72
LMNA P02545 1/20 0.64
CRYAB P02511 1/20 0.64
HMGCR P04035 1/20 0.59
FNTA P49354 1/20 0.59
FNTB P49356 1/20 0.59
BACE1 P56817 1/20 0.56
PREP P48147 1/20 0.52
PIN1 Q13526 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18688623 1.00 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL21149075 1.00 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL18688315 1.00 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL20990912 1.00 MAPT (0.85) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL5666302 0.92 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL17431708 0.92 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL6130526 0.92 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL2340127 0.92 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL415760 0.92 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15
SCHEMBL19194140 0.92 MAPT (1.00) MAPTUSP2ALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11207333-B2 Compositions comprising triterpenoids and uses thereof for treating optic neuropathy REGENERA PHARMA LTD. (IL) 2021-12-28 US disclosed
US-20190224217-A1 COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY REGENERA PHARMA LTD. (IL) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11207333-B2 Compositions comprising triterpenoids and uses thereof for treating optic neuropathy AQP4, CYP27A1, PMP22 MAPT 490/4885USP2 4207/4885ALDH1A1 1999/4885
US-20190224217-A1 COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY AQP4, CYP27A1, PMP22 MAPT 490/4885USP2 4207/4885ALDH1A1 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.